Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Lanreotyd kontra placebo przed operacją, aby zapobiec powikłaniu chirurgicznym zwanym przetoką trzustki

4 listopada 2026 zaktualizowane przez: SWOG Cancer Research Network

Randomizowane badanie o zaślepionym fazie III lanreotydu w celu zapobiegania pooperacyjnej przetoki trzustki

This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.

Przegląd badań

Szczegółowy opis

PRIMARY OBJECTIVE:

I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.

SECONDARY OBJECTIVES:

I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.

II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.

ADDITIONAL OBJECTIVES:

I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.

II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.

III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.

BANKING OBJECTIVE:

I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

274

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35233
        • Zawieszony
        • University of Alabama at Birmingham Cancer Center
      • Daphne, Alabama, Stany Zjednoczone, 36526
        • Zawieszony
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
      • Fairhope, Alabama, Stany Zjednoczone, 36532
        • Zawieszony
        • Thomas Hospital
      • Mobile, Alabama, Stany Zjednoczone, 36607
        • Zawieszony
        • Mobile Infirmary Medical Center
      • Saraland, Alabama, Stany Zjednoczone, 36571
        • Zawieszony
        • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
    • Arizona
      • Gilbert, Arizona, Stany Zjednoczone, 85234
        • Zawieszony
        • Banner MD Anderson Cancer Center
    • California
      • Duarte, California, Stany Zjednoczone, 91010
        • Zawieszony
        • City of Hope Comprehensive Cancer Center
      • La Jolla, California, Stany Zjednoczone, 92093
        • Rekrutacyjny
        • UC San Diego Moores Cancer Center
        • Kontakt:
        • Główny śledczy:
          • Andrew M. Lowy
      • Loma Linda, California, Stany Zjednoczone, 92357
        • Zawieszony
        • Veterans Affairs Loma Linda Healthcare System
      • Los Angeles, California, Stany Zjednoczone, 90033
        • Zawieszony
        • USC / Norris Comprehensive Cancer Center
      • San Diego, California, Stany Zjednoczone, 92103
        • Zawieszony
        • UC San Diego Medical Center - Hillcrest
    • Delaware
      • Newark, Delaware, Stany Zjednoczone, 19718
        • Zawieszony
        • Christiana Care Health System-Christiana Hospital
      • Newark, Delaware, Stany Zjednoczone, 19713
        • Zawieszony
        • Helen F Graham Cancer Center
      • Newark, Delaware, Stany Zjednoczone, 19713
        • Zawieszony
        • Medical Oncology Hematology Consultants PA
      • Wilmington, Delaware, Stany Zjednoczone, 19801
        • Zawieszony
        • Christiana Care Health System-Wilmington Hospital
    • Florida
      • Ruskin, Florida, Stany Zjednoczone, 33570
        • Zawieszony
        • Moffitt Cancer Center at SouthShore
      • Tampa, Florida, Stany Zjednoczone, 33612
        • Rekrutacyjny
        • Moffitt Cancer Center - McKinley Campus
        • Kontakt:
        • Główny śledczy:
          • Andrew J. Sinnamon
      • Tampa, Florida, Stany Zjednoczone, 33607
        • Zawieszony
        • Moffitt Cancer Center-International Plaza
      • Tampa, Florida, Stany Zjednoczone, 33612
        • Zawieszony
        • Moffitt Cancer Center
      • Wesley Chapel, Florida, Stany Zjednoczone, 33544
        • Zawieszony
        • Moffitt Cancer Center at Wesley Chapel
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30342
        • Zawieszony
        • Emory Saint Joseph's Hospital
      • Atlanta, Georgia, Stany Zjednoczone, 30308
        • Zawieszony
        • Emory University Hospital Midtown
      • Atlanta, Georgia, Stany Zjednoczone, 30322
        • Zawieszony
        • Emory University Hospital/Winship Cancer Institute
      • Atlanta, Georgia, Stany Zjednoczone, 30303
        • Zawieszony
        • Grady Health System
      • Johns Creek, Georgia, Stany Zjednoczone, 30097
        • Zawieszony
        • Emory Johns Creek Hospital
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Rekrutacyjny
        • Northwestern University
        • Kontakt:
        • Główny śledczy:
          • Akhil Chawla
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • Rekrutacyjny
        • University of Illinois
        • Główny śledczy:
          • Aslam Ejaz
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 312-355-3046
      • Geneva, Illinois, Stany Zjednoczone, 60134
        • Zawieszony
        • Northwestern Medicine Cancer Center Delnor
      • Oak Brook, Illinois, Stany Zjednoczone, 60523
        • Zawieszony
        • Northwestern Medicine Oak Brook
      • Orland Park, Illinois, Stany Zjednoczone, 60462
        • Zawieszony
        • Northwestern Medicine Orland Park
      • Warrenville, Illinois, Stany Zjednoczone, 60555
        • Zawieszony
        • Northwestern Medicine Cancer Center Warrenville
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Zawieszony
        • Indiana University/Melvin and Bren Simon Cancer Center
    • Kentucky
      • Lexington, Kentucky, Stany Zjednoczone, 40536
        • Rekrutacyjny
        • University of Kentucky/Markey Cancer Center
        • Główny śledczy:
          • Michael J. Cavnar
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 859-257-3379
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70112
        • Zawieszony
        • University Medical Center New Orleans
    • Maryland
      • Elkton, Maryland, Stany Zjednoczone, 21921
        • Zawieszony
        • Christiana Care - Union Hospital
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48109
        • Zawieszony
        • University of Michigan Rogel Cancer Center
      • Battle Creek, Michigan, Stany Zjednoczone, 49017
        • Zawieszony
        • Bronson Battle Creek
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Zawieszony
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Zawieszony
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Zawieszony
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
      • Muskegon, Michigan, Stany Zjednoczone, 49444
        • Zawieszony
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Stany Zjednoczone, 49120
        • Zawieszony
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Norton Shores, Michigan, Stany Zjednoczone, 49444
        • Zawieszony
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Stany Zjednoczone, 49677
        • Zawieszony
        • Corewell Health Reed City Hospital
      • Saint Joseph, Michigan, Stany Zjednoczone, 49085
        • Zawieszony
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Stany Zjednoczone, 49085
        • Zawieszony
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
      • Wyoming, Michigan, Stany Zjednoczone, 49519
        • Zawieszony
        • University of Michigan Health - West
    • Minnesota
      • Aitkin, Minnesota, Stany Zjednoczone, 56431
        • Zawieszony
        • Riverwood Healthcare Center
      • Baxter, Minnesota, Stany Zjednoczone, 56425
        • Zawieszony
        • Essentia Health - Baxter Clinic
      • Brainerd, Minnesota, Stany Zjednoczone, 56401
        • Zawieszony
        • Essentia Health Saint Joseph's Medical Center
      • Crosslake, Minnesota, Stany Zjednoczone, 56442
        • Zawieszony
        • Essentia Health - Saint Joseph's Crosslake Clinic
      • Deer River, Minnesota, Stany Zjednoczone, 56636
        • Zawieszony
        • Essentia Health - Deer River Clinic
      • Detroit Lakes, Minnesota, Stany Zjednoczone, 56501
        • Zawieszony
        • Essentia Health Saint Mary's - Detroit Lakes Clinic
      • Duluth, Minnesota, Stany Zjednoczone, 55805
        • Zawieszony
        • Essentia Health Saint Mary's Medical Center
      • Duluth, Minnesota, Stany Zjednoczone, 55805
        • Zawieszony
        • Miller-Dwan Hospital
      • Duluth, Minnesota, Stany Zjednoczone, 55805
        • Zawieszony
        • Essentia Health Cancer Center
      • Ely, Minnesota, Stany Zjednoczone, 55731
        • Zawieszony
        • Essentia Health - Ely Clinic
      • Fosston, Minnesota, Stany Zjednoczone, 56542
        • Zawieszony
        • Essentia Health - Fosston
      • Hibbing, Minnesota, Stany Zjednoczone, 55746
        • Zawieszony
        • Essentia Health Hibbing Clinic
      • International Falls, Minnesota, Stany Zjednoczone, 56649
        • Zawieszony
        • Essentia Health - International Falls Clinic
      • Moose Lake, Minnesota, Stany Zjednoczone, 55767
        • Zawieszony
        • Essentia Health - Moose Lake Clinic
      • Park Rapids, Minnesota, Stany Zjednoczone, 56470
        • Zawieszony
        • Essentia Health - Park Rapids
      • Pequot Lakes, Minnesota, Stany Zjednoczone, 56472
        • Zawieszony
        • Essentia Health - Saint Joseph's Pequot Lakes Clinic
      • Pine River, Minnesota, Stany Zjednoczone, 56474
        • Zawieszony
        • Essentia Health - Saint Joseph's Pine River Clinic
      • Sandstone, Minnesota, Stany Zjednoczone, 55072
        • Zawieszony
        • Essentia Health Sandstone
      • Staples, Minnesota, Stany Zjednoczone, 56479
        • Zawieszony
        • Essentia Health - Saint Joseph's Staples Clinic
      • Virginia, Minnesota, Stany Zjednoczone, 55792
        • Zawieszony
        • Essentia Health Virginia Clinic
    • Missouri
      • Farmington, Missouri, Stany Zjednoczone, 63640
        • Rekrutacyjny
        • Parkland Health Center - Farmington
        • Główny śledczy:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 314-996-5569
      • Sainte Genevieve, Missouri, Stany Zjednoczone, 63670
        • Rekrutacyjny
        • Sainte Genevieve County Memorial Hospital
        • Główny śledczy:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 314-996-5569
      • St Louis, Missouri, Stany Zjednoczone, 63131
        • Rekrutacyjny
        • Missouri Baptist Medical Center
        • Główny śledczy:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 314-996-5569
      • Sullivan, Missouri, Stany Zjednoczone, 63080
        • Rekrutacyjny
        • Missouri Baptist Sullivan Hospital
        • Główny śledczy:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 314-996-5569
      • Sunset Hills, Missouri, Stany Zjednoczone, 63127
        • Rekrutacyjny
        • BJC Outpatient Center at Sunset Hills
        • Główny śledczy:
          • Bryan A. Faller
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 314-996-5569
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68198
        • Zawieszony
        • University of Nebraska Medical Center
    • Nevada
      • Reno, Nevada, Stany Zjednoczone, 89502
        • Zawieszony
        • Renown Regional Medical Center
    • New Jersey
      • Livingston, New Jersey, Stany Zjednoczone, 07039
        • Zawieszony
        • Saint Barnabas Medical Center
      • New Brunswick, New Jersey, Stany Zjednoczone, 08903
        • Zawieszony
        • Rutgers Cancer Institute of New Jersey
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87106
        • Zawieszony
        • University of New Mexico Cancer Center
    • New York
      • Rochester, New York, Stany Zjednoczone, 14642
        • Zawieszony
        • University of Rochester
      • Syracuse, New York, Stany Zjednoczone, 13210
        • Zawieszony
        • State University of New York Upstate Medical University
    • North Carolina
      • Charlotte, North Carolina, Stany Zjednoczone, 28203
        • Zawieszony
        • Carolinas Medical Center/Levine Cancer Institute
      • Concord, North Carolina, Stany Zjednoczone, 28025
        • Zawieszony
        • Atrium Health Cabarrus/LCI-Concord
    • North Dakota
      • Fargo, North Dakota, Stany Zjednoczone, 58103
        • Zawieszony
        • Essentia Health Cancer Center-South University Clinic
      • Fargo, North Dakota, Stany Zjednoczone, 58122
        • Zawieszony
        • Sanford Roger Maris Cancer Center
      • Fargo, North Dakota, Stany Zjednoczone, 58122
        • Zawieszony
        • Sanford Broadway Medical Center
      • Jamestown, North Dakota, Stany Zjednoczone, 58401
        • Zawieszony
        • Essentia Health - Jamestown Clinic
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45219
        • Zawieszony
        • University of Cincinnati Cancer Center-UC Medical Center
      • Columbus, Ohio, Stany Zjednoczone, 43210
        • Zawieszony
        • Ohio State University Comprehensive Cancer Center
      • West Chester, Ohio, Stany Zjednoczone, 45069
        • Zawieszony
        • University of Cincinnati Cancer Center-West Chester
    • Pennsylvania
      • Allentown, Pennsylvania, Stany Zjednoczone, 18104
        • Rekrutacyjny
        • Saint Luke's Cancer Center - Allentown
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 610-776-4714
        • Główny śledczy:
          • Darius C. Desai
      • Bethlehem, Pennsylvania, Stany Zjednoczone, 18015
        • Rekrutacyjny
        • Saint Luke's University Hospital-Bethlehem Campus
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 484-503-4151
        • Główny śledczy:
          • Darius C. Desai
      • Chadds Ford, Pennsylvania, Stany Zjednoczone, 19317
        • Zawieszony
        • Christiana Care Health System-Concord Health Center
      • Easton, Pennsylvania, Stany Zjednoczone, 18045
        • Rekrutacyjny
        • Saint Luke's Hospital-Anderson Campus
        • Kontakt:
        • Główny śledczy:
          • Darius C. Desai
      • Quakertown, Pennsylvania, Stany Zjednoczone, 18951
        • Rekrutacyjny
        • Saint Luke's Hospital - Upper Bucks Campus
        • Kontakt:
          • Site Public Contact
          • Numer telefonu: 610-776-4714
        • Główny śledczy:
          • Darius C. Desai
      • Stroudsburg, Pennsylvania, Stany Zjednoczone, 18360
        • Rekrutacyjny
        • Saint Luke's Hospital - Monroe Campus
        • Kontakt:
        • Główny śledczy:
          • Darius C. Desai
      • Wilkes-Barre, Pennsylvania, Stany Zjednoczone, 18711
        • Zawieszony
        • Geisinger Wyoming Valley/Henry Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Stany Zjednoczone, 57104
        • Zawieszony
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
        • Zawieszony
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Knoxville, Tennessee, Stany Zjednoczone, 37920
        • Zawieszony
        • University of Tennessee - Knoxville
      • Memphis, Tennessee, Stany Zjednoczone, 38120
        • Zawieszony
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Vermont
      • Burlington, Vermont, Stany Zjednoczone, 05405
        • Zawieszony
        • University of Vermont and State Agricultural College
      • Burlington, Vermont, Stany Zjednoczone, 05401
        • Zawieszony
        • University of Vermont Medical Center
    • Virginia
      • Richmond, Virginia, Stany Zjednoczone, 23235
        • Rekrutacyjny
        • VCU Massey Cancer Center at Stony Point
        • Kontakt:
        • Główny śledczy:
          • Leopoldo J. Fernandez
      • Richmond, Virginia, Stany Zjednoczone, 23298
        • Rekrutacyjny
        • VCU Massey Comprehensive Cancer Center
        • Główny śledczy:
          • Leopoldo J. Fernandez
        • Kontakt:
      • Roanoke, Virginia, Stany Zjednoczone, 24033
        • Zawieszony
        • Carilion Roanoke Memorial Hospital
      • Winchester, Virginia, Stany Zjednoczone, 22601
        • Zawieszony
        • Valley Health / Winchester Medical Center
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98195
        • Zawieszony
        • University of Washington Medical Center - Montlake
      • Seattle, Washington, Stany Zjednoczone, 98109
        • Zawieszony
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Stany Zjednoczone, 54806
        • Zawieszony
        • Northwest Wisconsin Cancer Center
      • Ashland, Wisconsin, Stany Zjednoczone, 54806
        • Zawieszony
        • Duluth Clinic Ashland
      • Hayward, Wisconsin, Stany Zjednoczone, 54843
        • Zawieszony
        • Essentia Health-Hayward Clinic
      • Hayward, Wisconsin, Stany Zjednoczone, 54843
        • Zawieszony
        • Tamarack Health Hayward Medical Center
      • Marshfield, Wisconsin, Stany Zjednoczone, 54449
      • Mukwonago, Wisconsin, Stany Zjednoczone, 53149
        • Zawieszony
        • ProHealth D N Greenwald Center
      • Oconomowoc, Wisconsin, Stany Zjednoczone, 53066
        • Zawieszony
        • ProHealth Oconomowoc Memorial Hospital
      • Spooner, Wisconsin, Stany Zjednoczone, 54801
        • Zawieszony
        • Essentia Health-Spooner Clinic
      • Superior, Wisconsin, Stany Zjednoczone, 54880
        • Zawieszony
        • Essentia Health Saint Mary's Hospital - Superior
      • Waukesha, Wisconsin, Stany Zjednoczone, 53188
        • Zawieszony
        • ProHealth Waukesha Memorial Hospital
      • Waukesha, Wisconsin, Stany Zjednoczone, 53188
        • Zawieszony
        • UW Cancer Center at ProHealth Care

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential

  • Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date

  • Participants must not have a known history of a prior diagnosis of malabsorption syndrome

  • Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization

  • Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization

  • Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization

  • Participants must be ≥ 18 years old

  • Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization

  • Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization

  • Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:

    • Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
    • Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
    • Bromocriptine: Dose adjustments may be considered to account for absorption changes
    • Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
    • CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy

    • NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
  • In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation

  • Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable

  • Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)

  • Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking

  • Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study

  • NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

  • For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Arm I (lanreotide, distal pancreatectomy)

Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Inne nazwy:
  • Pobieranie próbek biologicznych
  • Zebrano próbki biologiczne
  • Kolekcja próbek

Undergo distal pancreatectomy

Given SC

Inne nazwy:
  • Ipstyl
  • Somatulina
  • Angiopeptyna
  • BIM-23014
  • DC 13116
  • Dermopepeptyna
Komparator placebo: Arm II (saline placebo, distal pancreatectomy)

Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.

Ancillary studies

Undergo blood sample and pancreas fluid collection

Inne nazwy:
  • Pobieranie próbek biologicznych
  • Zebrano próbki biologiczne
  • Kolekcja próbek

Undergo distal pancreatectomy

Given SC

Inne nazwy:
  • Chlorek Sodu 0,9%
  • Zwykła sól fizjologiczna
  • IZOTONOWY ROZTWÓR CHLOREKU SODU

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Incidence of postoperative pancreatic fistula (POPF)
Ramy czasowe: Up to 60 days after distal pancreatectomy

POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Incidence of biochemical leak (BL)
Ramy czasowe: Up to 60 days after distal pancreatectomy

BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Number of post-operation hospital days
Ramy czasowe: From the time of surgery up to 60 days after distal pancreatectomy

Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor.

From the time of surgery up to 60 days after distal pancreatectomy
Change in overall quality of life (QOL)
Ramy czasowe: At baseline and at 14 and 60 days after surgery

Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and at 14 and 60 days after surgery

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Changes in pancreatic specific QOL
Ramy czasowe: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Change in health-related QOL
Ramy czasowe: At baseline and up to 60 days after distal pancreatectomy

Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures.

At baseline and up to 60 days after distal pancreatectomy
Delayed gastric emptying (DGE)
Ramy czasowe: Up to 60 days after distal pancreatectomy

DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Ramy czasowe: Up to 60 days after distal pancreatectomy

PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor.

Up to 60 days after distal pancreatectomy
Time to initiation of adjuvant chemotherapy
Ramy czasowe: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy

Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test.

From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
Incidence of nausea and vomiting
Ramy czasowe: Up to 60 days after distal pancreatectomy

Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test.

Up to 60 days after distal pancreatectomy

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Jonathan G Sham, SWOG Cancer Research Network

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 maja 2025

Zakończenie podstawowe (Szacowany)

1 kwietnia 2029

Ukończenie studiów (Szacowany)

1 kwietnia 2029

Daty rejestracji na studia

Pierwszy przesłany

29 stycznia 2025

Pierwszy przesłany, który spełnia kryteria kontroli jakości

29 stycznia 2025

Pierwszy wysłany (Rzeczywisty)

4 lutego 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

6 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

4 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj